
Carl Dambkowski, MD
CMO, Apogee TherapeuticsDr Dambkowski is Chief Medical Officer for Apogee Therapeutics.
He has spent the last 10 years as a strategic and clinical leader advising biotech and pharma companies on a range of research and development activities. Prior to joining Apogee, he was part of the core teams at QED Therapeutics and Origin Biosciences as they brought TRUSELTIQ (infigratinib) and NULIBRY (fosdenopterin) through regulatory review and FDA approval. Additionally, he has served as Associate at McKinsey & Company and co-founded the private medical device company Novonate, Inc.
Dr Dambkowski holds a BS and MD from Stanford University in addition to an MA from Columbia University.